{"id":"lamivudine-oxymatrine-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Lactic acidosis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Gastrointestinal disturbance"}]},"_chembl":{"chemblId":"CHEMBL458337","moleculeType":"Small molecule","molecularWeight":"264.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV and hepatitis B virus replication by inhibiting reverse transcriptase. Oxymatrine, an alkaloid from Sophora flavescens, has immunomodulatory properties and may enhance antiviral immunity while providing hepatoprotective effects. The combination targets both viral suppression and immune enhancement in chronic viral infections.","oneSentence":"Lamivudine inhibits reverse transcriptase to suppress viral replication, while oxymatrine provides immunomodulatory and hepatoprotective effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:51:31.459Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"},{"name":"HIV infection (as part of combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT02202473","phase":"PHASE4","title":"Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects","status":"COMPLETED","sponsor":"Southeast University, China","startDate":"","conditions":"Chronic Hepatitis B","enrollment":192}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lamivudine+Oxymatrine Capsules","genericName":"Lamivudine+Oxymatrine Capsules","companyName":"Southeast University, China","companyId":"southeast-university-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lamivudine inhibits reverse transcriptase to suppress viral replication, while oxymatrine provides immunomodulatory and hepatoprotective effects. Used for Chronic hepatitis B infection, HIV infection (as part of combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}